Bayer's Nexavar disappoints in breast cancer

Share this article:

Bayer and Amgen clocked another failed indication-expansion effort for the cancer drug Nexavar. The companies announced Friday the drug did not hit its Phase-III primary target of improving progression-free survival among patients receiving both Nexavar and chemotherapy. The RESILIENCE study focused on patients with HER2-negative breast cancer who are resistant to, or failed on, taxane therapy or who have failed on anthracycline or for whom anthracycline is not indicated.

The companies also had a setback in March when they announced Nexavar failed to hit the Phase-III target of recurrence-free survival among liver-cancer patients when used as an adjuvant therapy.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.